Supplementary Table 1. Overview of Publication Dates of Other Published HTAs on Drugs Assessed by LBI-HTA (as of July 2012)

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug** | **Indication** | **EMA approval date** | **HTA institutes and publication dates** |
| Azacitidine | Myelodysplastic syndrome | 12/2008 | * [NHSC 09/2007](http://www.nhsc-healthhorizons.org.uk/files/downloads/1169/1675.c094ba6c4d03b010dfc8e7c29798d247.pdf)
* [HAS 04/2009](http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-07/vidaza_ct_6362.pdf)
* LBI-HTA 08/2009
* [NICE 03/2011](http://www.nice.org.uk/nicemedia/live/13418/53609/53609.pdf)
* [SMC 08/2011](http://www.scottishmedicines.org.uk/files/advice/azacitidine_Vidaza_RESUBMISSION_FINAL_August_2011_for_website.pdf)
 |
| Cetuximab | EGFR-expressing non-small cell lung cancer | 07/2009 Refusal of market authorization | * [NHSC 08/2006](http://www.nhsc-healthhorizons.org.uk/files/downloads/1194/1699.dd92d7b7bccae9ad0ba65ef067d270c4.pdf)
* LBI-HTA 09/2009
 |
| Everolimus | Second-line therapy for advanced/metastatic kidney cancer | 08/2009 | * [NHSC 04/2008](http://www.nhsc-healthhorizons.org.uk/topics/everolimus-rad-001-for-renal-cell-carcinoma-advanc/)
* LBI-HTA 09/2009
* [NETSCC 11/2009](http://www.hta.ac.uk/erg/reports/2155.pdf)
* [AKDAE 11/2009](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2009009-Afinitor.pdf)
* [HAS 01/2010](http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-12/afinitor_ct_7009.pdf)
* [NICE 04/2011](http://www.nice.org.uk/nicemedia/live/13437/54111/54111.pdf)
 |
| Rituximab | First- and Second- line chronic lymphocytic leukemia | 01/2009 | * [NHSC 09/2007](http://www.nhsc-healthhorizons.org.uk/files/downloads/1176/1682.53bb899d6bd2144c858930762d5096f7.pdf)
* [NETSCC 01/2009](http://www.hta.ac.uk/erg/reports/2052.pdf)
* [NICE 07/2009](http://guidance.nice.org.uk/TA174/Guidance/pdf/English)
* [AKDAE 05/2009](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2009003-MabThera.pdf)
* LBI-HTA 10/2009
* HAS 01/2010
 |
| Ibritumomab tiuxetan | Consolidation therapy for follicular lymphoma | 04/2008 | * [SMC 07/2007](http://www.scottishmedicines.org.uk/files/ibritumomab_tiuxetan__Zevalin__Resubmission_FINAL_June_2007_for_website.pdf)
* LBI-HTA 12/2009
 |
| Gefitinib | First-line non-small cell lung cancer | 06/2009 | * [NETSCC 11/2009](http://www.hta.ac.uk/erg/reports/2152.pdf)
* [HAS 11/2009](http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/iressa_ct_6839.pdf)
* LBI-HTA 12/2009
* [NICE 07/2010](http://www.nice.org.uk/nicemedia/live/13058/49880/49880.pdf)
* [NCPE 11/2010](http://www.ncpe.ie/wp-content/uploads/2010/11/Summary.pdf)
 |
| Trabectedin  | Second-line recurrent platinum-sensitive ovarian cancer | 09/2009 | * [NHSC 12/2007](http://www.nhsc-healthhorizons.org.uk/files/downloads/1165/1671.3a67544c22301865952192ad2e0465fc.pdf)
* LBI-HTA 11/2009
* [AKDAE 03/2010](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2010012-Yondelis.pdf)
* [SMC 08/2010](http://www.scottishmedicines.org.uk/files/advice/trabectedin_Yondelis.pdf)
* [NICE 04/2011](http://guidance.nice.org.uk/TA222/Guidance/pdf/English)
 |
| Plerixafor | Autologous stem cell transplantation in patients with lymphoma and multiple myeloma | 07/2009 | * NHSC 12/2007
* [HAS 12/2009](http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/mozobil_ct_7232.pdf)
* [SMC 12/2009](http://www.scottishmedicines.org.uk/files/plerixafor__Mozobil__FINAL_December_2009.doc_for_website.pdf)
* LBI-HTA 03/2010
 |
| Lapatinib | First-line advanced/metastatic breast cancer | 05/2010 | * [NHSC 01/2010](http://www.nhsc-healthhorizons.org.uk/files/downloads/1098/1604.0a6af6b41ffbff6bc0be09345d467b66.pdf)
* LBI-HTA 05/2010
* [AKDAE 12/2010](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv-INN/2010016-Tyverb.pdf)
 |
| Bendamustine | Indolent non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma  | 03/2010 Approval not granted for all European countries | * LBI-HTA 07/2010
* [NICE 10/2010](http://www.nice.org.uk/nicemedia/live/13254/51330/51330.pdf)
 |
| Panitumumab | First-line treatment of metastatic colorectal cancer | 11/2011 Conditional marketing authorization | * [NHSC 06/2008](http://www.nhsc-healthhorizons.org.uk/files/downloads/1137/1643.fff8f4108e09194bd40f45f82b2fdf92.pdf)
* LBI-HTA 06/2010
 |
| Trastuzumab | First-line advanced gastric cancer | 01/2010 | * [NHSC 09/2007](http://www.nhsc-healthhorizons.org.uk/files/downloads/1858/1683.db0baa6a.Trastuzumab.pdf)
* LBI-HTA 05/2010
* [SMC [07/2010](http://www.scottishmedicines.org.uk/files/trastuzumab_Herceptin_FINAL_July_2010_amended_04_Aug_2010.pdf) and resubmission in 01/2011](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/623_10_trastuzumab_Herceptin/trastuzumab_Herceptin_Resubmission)
* [NICE 11/2010](http://guidance.nice.org.uk/TA208)
 |
| Pazopanib | First-line therapy of locally advanced and/or metastatic renal cell carcinoma | 06/2010 | * [NHSC 04/2008](http://www.nhsc-healthhorizons.org.uk/files/downloads/1149/1655.47a93c43c9eb465a171812909d80edff.pdf)
* LBI-HTA 10/2010
* [AKDAE 12/2010](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2010016-Votrient.pdf)
* [NICE 02/2011](http://www.nice.org.uk/nicemedia/live/13346/53185/53185.pdf)
* [SMC 03/2011](http://www.scottishmedicines.org.uk/files/advice/pazopanib_Votrient_FINAL_February_2011.doc_for_website.pdf)
* [HAS 02/2011](http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-06/votrient_ct_8713.pdf)
 |
| Ipilimumab | Pre-treated patients with advanced/metastatic melanoma | 07/2011 | * [NHSC 04/2008](http://www.nhsc-healthhorizons.org.uk/files/downloads/1146/1652.f1ab690f8575654204e277a3c1642c08.pdf)
* LBI-HTA 12/2010
* [NCPE 09/2011](http://www.ncpe.ie/wp-content/uploads/2012/03/Ipilimumab-Yervoy-summary.pdf)
* [AKDAE 11/2011](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2011031-Yervoy.pdf)
 |
| Nilotinib | First-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase | 12/2010 | * [NHSC 06/2008](http://www.nhsc-healthhorizons.org.uk/files/downloads/1135/1641.84cfb109824400b5ab990d6128ad480d.pdf)
* LBI-HTA 01/2011
* [SMC 07/2011](http://www.scottishmedicines.org.uk/files/advice/nilotinib_Tasigna_FINAL_July_2011_for_website.pdf)
 |
| Cabazitaxel | Second-line chemotherapy for castration-resistant metastatic prostate cancer | 03/2011 | * [NHSC 04/2009](http://www.nhsc-healthhorizons.org.uk/files/downloads/1114/1620.57c5f0aea7125ceb4d54424ffb8f2c6b.pdf)
* LBI-HTA 02/2011
* [AKDAE 08/2011](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2011023-Jevtana.pdf)
* [SMC 10/2011](http://www.scottishmedicines.org.uk/files/advice/cabazitaxel_Jevtana_FINAL_October_2011_for_website.pdf)
* [IQWiG 01/2012](https://www.iqwig.de/a11-24-cabazitaxel-nutzenbewertung-gemaess-35a.986.html?tid=1454)
* [NCPE 03/2012](http://www.ncpe.ie/wp-content/uploads/2011/06/Cabazitaxel-Summary-for-website.pdf)
 |
| Dasatinib | First-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase | 12/2010 | * [NHSC 09/2009](http://www.nhsc-healthhorizons.org.uk/files/downloads/1106/1612.5d222f7d875be03adf4d283de3045097.pdf)
* LBI-HTA 02/2011
 |
| Eribulin | Third- or late-line mono-therapy for advanced/metastatic breast cancer | 03/2011 | * [NHSC 04/2009](http://www.nhsc-healthhorizons.org.uk/files/downloads/1115/1621.4335d3c2d4bca6e3e794c912d56a91d0.pdf)
* LBI-HTA 06/2011
* [AKDAE 10/2011](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2011027-Halaven.pdf)
* [SMC 10/2011](http://www.scottishmedicines.org.uk/files/advice/eribulin_Halaven_FINAL_September_2011_for_website.pdf)
* [IQWiG 01/2012](https://www.iqwig.de/a11-26-eribulin-nutzenbewertung-gemaess-35a-sgb-v.986.html?tid=1456)
 |
| S-1 | First-line therapy for patients with advanced non-small cell lung cancer | 03/2011 | * LBI-HTA 07/2011
 |
| Abiraterone acetate | Second-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy | 09/2011 | * [NHSC 05/2010](http://www.nhsc-healthhorizons.org.uk/files/downloads/1084/1590.463cc9497daf9bc5b3911538072a0f20.pdf)
* LBI-HTA 11/2011
* [AKDAE 11/2011](http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2011032-Zytiga.pdf)
* [IQWiG 12/2011](https://www.iqwig.de/a11-20-abirateronacetat-nutzenbewertung-gemaess.986.html?tid=1448)
* [SMC 02/2012](http://www.scottishmedicines.org.uk/files/advice/abiraterone_Zytiga_FINAL_February_2012_AB_Revised_02.03.12_for_website.pdf)
 |
| Axitinib | Second- line treatment of metastatic renal cell carcinoma  | NA | * [NHSC 08/2010](http://www.nhsc-healthhorizons.org.uk/files/downloads/1073/1579.6b23d6f79f5ed75161c5ef7f2c0cf4da.pdf)
* LBI-HTA 01/2012
 |
| Erlotinib | First- line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations | 09/2011 | * AHRQ 11/2005
* [NHSC 08/2010](http://www.nhsc-healthhorizons.org.uk/files/downloads/1075/1581.6661df2d256d6462a9e74f2bf8547ab5.pdf)
* [NETSCC 11/2011](http://www.hta.ac.uk/erg/reports/2644.pdf)
* LBI-HTA 01/2012
 |
| Vemurafenib | *BRAF* V600E mutation positive advanced/metastatic melanoma | 02/2012 | * LBI-HTA 01/2012
 |
| Everolimus | Unresectable or metastatic neuroendocrine tumors of pancreatic origin | 08/2011 | * [NHSC 05/2008](http://www.nhsc-healthhorizons.org.uk/files/downloads/1138/1644.321f515d936bd9baa37035b7205af656.pdf)
* LBI-HTA 12/2011
 |

Abbreviations: AHRQ = Agency for Healthcare Research and Quality; AKDAE = Drug Commission of the German Medical Association; EGFR = epidermal growth factor receptor; EMA = European Medicines Agency; HAS = Haute Autorité de santé; HTA = Health Technology Assessment; IQWiG = Institute for Quality and Efficiency in Healthcare; LBI-HTA = Ludwig Boltzmann Institute for Health Technology Assessment; NA = not applicable; NCPE = National Centre for Pharmacoeconomics; NHSC = National Horizon Scanning Centre Birmingham; NICE = National Institute for Health and Clinical Excellence; NETSCC = NIHR Evaluation, Trials and Studies Coordinating Centre; SMC = Scottish Medicines Consortium.